Abstract
Intrahepatic cholangiocarcinoma (iCCA) is a rare malignancy of the intrahepatic biliary tract with a very poor prognosis. Although some clinicopathological parameters can be prognostic factors for iCCA, the molecular prognostic markers and potential mechanisms of iCCA have not been well investigated. Here, we report that the Fragile X mental retardation protein (FMRP), a RNA binding protein functionally absent in patients with the Fragile X syndrome (FXS) and also involved in several types of cancers, is overexpressed in human iCCA and its expression is significantly increased in iCCA metastatic tissues. The silencing of FMRP in metastatic iCCA cell lines affects cell migration and invasion, suggesting a role of FMRP in iCCA progression. Moreover, we show evidence that FMRP is localized at the invasive front of human iCCA neoplastic nests and in pseudopodia and invadopodia protrusions of migrating and invading iCCA cancer cells. Here FMRP binds several mRNAs encoding key proteins involved in the formation and/or function of these protrusions. In particular, we find that FMRP binds to and regulates the expression of Cortactin, a critical regulator of invadopodia formation. Altogether, our findings suggest that FMRP could promote cell invasiveness modulating membrane plasticity and invadopodia formation at the leading edges of invading iCCA cells.
Subject terms: Liver cancer, Mechanisms of disease
Introduction
Intrahepatic cholangiocarcinoma (iCCA) is a primary cancer of the bile ducts arising from the malignant transformation of biliary epithelial cells and is characterized by an aggressive behavior with early lymphatic and metastatic spread and very poor prognosis [1]. iCCA is relatively uncommon, but its incidence is on the increase [2]. Up to date, surgical resection of iCCA represents the only potentially curative therapeutic option, but most of the patients are ineligible for curative surgery because of the presence of metastases at the time of diagnosis [3]. Therefore, the identification of molecular biomarkers, as well as novel promising molecules for targeted therapy development is of primary importance in iCCA clinical management.
Here, we investigated the role of the Fragile X Mental Retardation Protein (FMRP) in iCCA. FMRP is a selective RNA binding protein whose functional absence causes the Fragile X Syndrome (FXS), an X-linked neurological disorder that represents the most common form of inherited intellectual disability in humans [4, 5]. FMRP has been largely studied and characterized in brain and, in particular, in neurons where its functional absence causes dendritic spine dysmorphogenesis [6–8]. The FMRP mRNA target-transcriptome was characterized in neurons [9–12], and an IPA analysis of FMRP-regulated mRNAs has shown that these targets are mainly involved in cytoskeleton remodeling and cell-to-cell signaling and interaction [6], mechanisms also involved in cancer progression. Indeed, it was recently shown that FMRP is also involved in progression of breast cancer [13], astrocytoma [14], malignant pleural mesothelioma [15], melanoma [16], and colon cancer [17]. Of note, in melanoma cells we identified the FMRP-regulated transcriptome that further confirmed its implication in the invasion of the tumor [16]. In agreement with these data, a decreased risk of cancer [13, 18], as well as an unusual reduction of cancer invasiveness [19] in individuals with FXS, have been observed.
Finally, some evidence suggests an involvement of FMRP in hepatic and pancreatic cancers [20–23]. In particular, FMR1 gene, encoding for FMRP, is overexpressed in both pre-neoplastic and neoplastic stages of HCC [20, 21] and was identified as a metastasis-related gene in an HCC cell line derived from lung metastatic lesions [22], as well as a downstream effector of NMDAR signaling pathway that influences invasive tumor growth in a mouse model of pancreatic neuroendocrine tumor (PanNET) [23].
Despite this evidence in liver and pancreatic cancers, the role of FMRP in cholangiocarcinoma has never been investigated before. Here we show that FMRP is overexpressed in a selected cohort of human iCCA and in particular the highest levels of expression are found in metastatic tissues. Furthermore, in metastatic iCCA cell lines, the silencing or the overexpression of FMRP influences cellular migration and invasion, suggesting a role of FMRP in iCCA progression. At the cellular level, by confocal microscopy, immunogold electron microscopy (EM) and time-lapse live imaging, FMRP was found in cytoplasmic RNA granules accumulating in the protrusions of the plasma membrane involved in migration and invasion, such as pseudopodia and invadopodia, respectively. Of note, the reduction of FMRP expression decreases the ability of iCCA cells to form invadopodia protrusions and to degrade extracellular matrix in vitro. Finally, using a co-immunoprecipitation/NanoString nCounter® approach we demonstrated that FMRP is able to bind several mRNAs encoding key proteins required for pseudopodia and invadopodia formation and function. In particular, FMRP is able to bind Cortactin (CTTN) mRNA and to regulate the expression of Cortactin, a critical regulator of invadopodia formation. Our data strongly suggest a role for FMRP in regulating mRNA metabolism at the leading edges of iCCA cells.
Results
FMRP is overexpressed in human iCCA and its levels correlate with the metastatic phenotype
The expression and the intra-tissue distribution of FMRP were evaluated by immunohistochemistry (IHC) in a cohort of iCCAs (n = 48) and non-tumoral hepatic tissues (n = 7). In non-tumoral hepatic tissues, cholangiocytes of bile ducts were negative (IHC score = 0) or showed low FMRP expression (IHC score = 1), while a clear immunopositivity was found in the surrounding hepatocytes (Fig. 1a, left panel, NT region and right panel, see asterisk). However, in iCCA FMRP was detected (Fig. 1a, left panel, T region) with an expression level ranging from low (IHC score = 1) to high (IHC score = 2) (Fig. 1b, c), and with an overall significant overexpression in the tumor tissues, compared to non-neoplastic bile ducts (Fig. 1c, left panel). In particular, the FMRP immunopositivity was mainly found at the margins of the neoplastic glands or nests, close to the neighboring stromal tissue (tumor-stromal interface) (Fig. 1d, see arrowheads).
Interestingly, a comparative analysis with clinic-pathological parameters highlighted a significant correlation between FMRP expression and metastatic nature of iCCA tissues, suggesting a role for FMRP in iCCA progression and metastatization (Fig. 1e).
Conversely, in a cohort of extrahepatic cholangiocarcinomas (eCCA) (n = 17) FMRP was not significantly overexpressed compared to non-tumoral hepatic tissues (Supplementary Fig. 1a), suggesting that the different FMRP expression might be due to the different nosological entity of the iCCA respect to eCCA.
Next, we evaluated the FMRP expression levels in an immortalized intrahepatic normal human biliary epithelial cell line (H69) [24], in three human metastatic eCCA cell lines (KMBC, TFK-1 and MzChA1) and in two human metastatic iCCA cell lines (HuCCT and HuH28) [25]. FMRP and FMR1 mRNA were significantly overexpressed in the two iCCA cell lines compared to both non-transformed biliary epithelial cells and eCCA cell lines (Fig. 1f for proteins and Fig. 1g for mRNAs), in agreement with the IHC data.
FMRP is localized at the leading edges of iCCA cells
We also investigated the intracellular distribution of FMRP in iCCA cells. In human iCCA tissues IHC revealed a dotted positivity pattern linearly gathered under plasma membrane (Fig. 2a, top panels, see black arrowheads), very similar to the pattern of Cortactin protein (Fig. 2a, bottom panels, see white arrowheads), a key regulator of actin cytoskeleton dynamics and cell shape at the leading edges [26]. Using immunocytochemistry EM we also observed FMRP gold particles localized inside and at the base of membrane protrusions at the leading edges of both HuCCT (Fig. 2b, white arrowheads) and HuH28 (Supplementary Fig. 1b, white arrowheads) cells, sometimes near Cortactin gold particles (Fig. 2b, black arrows) and polyribosomes aggregates (Fig. 2b, white arrows).
FMRP is localized in pseudopodia protrusions at the leading edge of migrating iCCA cells
Invasive cell migration requires sustained forward movement of the plasma membrane at the cellular front or leading edge and is preceded by the formation of pseudopodia structures such as lamellipodia and filopodia [27]. To investigate whether FMRP–containing granules observed in iCCA cells (Fig. 2) were also present inside cell protrusions in fibronectin-migrating cells, we performed a fluorescent immunocytochemical analysis of FMRP, and simultaneously stained cell protrusions with Cortactin or MT1-MMP, two proteins enriched in both lamellipodia and invadopodia structures [28, 29]. Interestingly, FMRP granules localized in pseudopodia (filopodia or lamellipodia) protrusions at the leading edge of HuH28 and HuCCT cells (Fig. 3, red arrowheads), which also contained Cortactin (Fig. 3a, green arrowheads) and MT1-MMP (Fig. 3b, green arrowheads). Only rarely FMRP-Cortactin or FMRP-MT1-MMP colocalization foci were observed (Figs. 3a, b, yellow arrowheads), suggesting that, although present within the same cell protrusions, these proteins probably are not part of the same protein complexes. Moreover, using immunofluorescence we could detect an enrichment of FMRP granules in the distal part of the protrusions compared to proximal and medial parts (Supplementary Fig. 1c).
In addition, time-lapse live imaging of migrating HuCCT cells overexpressing FMRP-GFP, showed cytoplasmic FMRP granules moving along cell protrusions (lamellipodia and filopodia) at the leading edge (Fig. 3c and Supplementary Information Movies 1, 2), while HuCCT control cells expressing GFP showed a diffuse, uniform and not polarized signal (Supplementary Information Movie 3).
FMRP is localized in invadopodia of iCCA cells
Proteolytic degradation of extracellular matrix (ECM) is a critical step during cancer cell invasion and invadopodia are the protrusions situated in the ventral cell surface and often under the nucleus, that mediate cell adhesion to, degradation of, and invasion into ECM in tumor cells [30]. To verify the presence of FMRP also in these protrusions, we performed a Cy3-gelatin degradation assay (GDA) and 19 h later we detected FMRP protein by confocal imaging both in HuH28 (Fig. 4a) and HuCCT cells (Fig. 4b). Since HuCCT cells were found to be poorly prone to gelatin degradation (GD) (24 h of incubation showed no or limited GD, data not shown), we stimulated invadopodia formation with starvation and MMP deprivation before GDA (see “Material and Methods”). In both HuH28 (Fig. 4a) and HuCCT cells (Fig. 4b) FMRP was found to localize in mature-late stages of invadopodia [31] that are inside the black area of gelatin (GD), and in mature-early stages or precursor-late stages of invadopodia [31] that reside in the non-degraded gelatin. The orthogonal view (Z stack) of FMRP staining showed that FMRP foci are localized in the ventral part of the cells, mainly under the nucleus (Fig. 4, white arrowheads), consistent with the invadopodia localization [30]. In particular, in HuCCT cells, which are thicker than HuH28 cells, 3D confocal reconstruction clearly showed FMRP in invadopodia protrusions in the ventral and sub-nuclear area of the cell (Fig. 4c).
Interestingly, FMRP and F-actin double staining showed that FMRP foci frequently localize in degradation spots with no F-actin puncta and only rarely in F-actin enriched mature-late invadopodia (Supplementary Fig. 2, white arrowheads in orthogonal view). Of note, the localization of FMRP in invadopodia seems to be common also to other cancer cells, such as the A375 melanoma cells (Supplementary Fig. 3), for which the role of FMRP in cancer progression has been previously investigated [16].
FMRP silencing affects migration, invasion, and invadopodia formation in iCCA cells
To verify the role of FMRP in motility and invasion in iCCA cells, FMRP expression was knocked down both in HuH28 and HuCCT cells. Because HuH28 cells have a low duplication time, it was not possible to perform a stable knock down, therefore HuH28 cells were transiently transfected with specific FMR1 siRNAs and FMRP knockdown was confirmed by western blotting (Supplementary Fig. 4a). On the contrary, we succeeded in generating HuCCT cells with stable expression of FMR1 specific shRNAs using a lentiviral vector and found a consistent downregulation of FMRP and FMR1 mRNA levels (Supplementary Fig. 4b). FMRP knockdown in HuCCT cells resulted in a certain attenuation of growth as subcutaneous xenografts in nude mice, but this effect did not reach statistical significance (Supplementary Fig. 4c). However, reduction of FMRP expression did have a marked effect on cell migration and invasion in vitro. Indeed, FMRP knockdown reduced cell motility into a wounded area of confluent cultures in HuH28 (Fig. 5a) and HuCCT cells (Fig. 5b). Accordingly, in trans-well migration assays, motility of HuH28 and HuCCT was significantly lower in FMR1-knockdown cells compared to untransfected controls, or in scrambled siRNA or CTR shRNA transfected cells (Fig. 5c, migration panels). Similarly, in trans-well invasion assays, FMR1-knockdown HuH28 or HuCCT cells were consistently and significantly less invasive than the respective controls (Fig. 5c, invasion panels). Conversely, the overexpression of FMRP in HuCCT cells (Supplementary Fig. 5a, b) increases both migration and invasion capabilities, in trans-well assays (Supplementary Fig. 5c). Notably, the survival rate of both iCCA cell lines in FMRP silenced versus control conditions did not change, excluding a relevant effect of FMRP on proliferation and/or cell death during migration and invasion assays (Supplementary Fig. 6).
Altogether, these data confirm the involvement of FMRP in modulating the migratory and invasive properties of iCCA cells.
To investigate the involvement of FMRP in invadopodia formation we performed GDAs in FMRP silenced HuH28 and HuCCT cells. FMRP silencing significantly reduced (>60%) the cellular capability to degrade Cy3-gelatin, both in HuH28 (Fig. 6a, c, left panel) and HuCCT cells (Fig. 6b, c, right panel). Of note, in FMRP silenced HuH28 cells the less invasive behavior is accompanied by a particular change in the cell morphology, with cells appearing to have a rounder shape compared to the more front-rear and migrating morphology of control cells (Supplementary Fig. 7). However, in HuCCT cells the changes in the cellular shape were not observed (data not shown), probably due to stimulation conditions pre-GDA assays.
FMRP binds mRNAs encoding key proteins involved in invadopodia formation and function
To explore the possibility that FMRP could represent a regulator of local mRNA metabolism in pseudopodia/invadopodia, we immunoprecipitated FMRP complex from HuH28 cells with a specific commercially available anti-FMRP polyclonal antibody (ab17722) and, in FMRP co-immunoprecipitated RNA pool, we checked the presence of mRNAs encoding for key proteins involved in invadopodia formation and function (Fig. 7a) using the NanoString nCounter® technology (Supplementary Fig. 8a).
As reported in Fig. 7a, CTTN, FMR1, MMP1, MMP9, and SRC mRNAs are consistently (fold change > 2.0 and log10fold change > 0.3; dashed threshold line in Fig. 7a) and significantly enriched in FMRP co-IP mRNA pool compared to IgG-IP nonspecific mRNAs, demonstrating that these mRNAs are targets of FMRP in HuH28 cells (Fig. 7a). As negative control, the three housekeeping genes GAPDH, HPRT1, and TUBB were not co-immunoprecipitated with FMRP complex (Fig. 7a). To verify if FMRP is able to modulate the expression of the proteins encoded by the FMRP mRNA targets, we analysed protein extracts from control HuH28 cells (untransfected CTR or scr siRNA transfected cells) or FMRP silenced cells (FMR1 siRNA) performing a Western blot. Interestingly, FMRP knockdown significantly reduced the expression of Cortactin, a marker of mature invadopodia, while had not effect on the abundance of the other proteins involved in invadopodia formation (Fig. 7b). This decrease was clearly visible in FMRP silenced HuH28 cells also by IF experiments (Supplementary Fig. 8b).
In agreement with these findings, FMRP and Cortactin expressions showed a direct correlation in iCCA samples of TGCA data set (Fig. 7c), and in the cohort of iCCA samples analysed in this study (Fig. 7d). Finally, this direct correlation between FMRP and Cortactin expression was also observed in xenograft tumors from nude mice injected with stably transfected FMR1 shRNA or CTR shRNA HuCCT cells. In these tumors, FMRP knockdown was associated with reduced Cortactin staining, and regions of intense FMRP immunostaining corresponded to high levels of Cortactin signal (Fig. 7e).
Discussion
Although some clinicopathological parameters, including lymph node metastasis and tumor differentiation, have been shown to be prognostic factors for iCCA [32, 33], the identification of molecular prognostic markers and the understanding of the pathogenic mechanisms involved in iCCA are still far off [34, 35].
Our work revealed that FMRP could have a pathogenetic role in iCCA progression. Indeed, we showed that FMRP is highly expressed in human iCCA tissues, and its expression levels significantly correlate with the metastatic nature of iCCA tissues. Accordingly, the modulation of FMRP levels in iCCA cell lines by silencing or overexpression impairs or increases their invasive and migratory capacities, which play a central role in metastatization [36, 37].
About the molecular mechanism by which FMRP could have such a pathogenetic effect, we observed that it is particularly enriched in the cells localized at the tumor-host interface (named “invasive tumor front” ITF) [38], with a peculiar intracellular dotted and under-membrane localization which resembles the neuronal pattern [39] and which suggests a common function for FMRP in all polarized cells: the local regulation of mRNA metabolism (localization, stability, and local protein synthesis) at the leading edge.
mRNA localization and local protein synthesis have a fundamental importance for the establishment and maintenance of cancer cell polarity during migration and invasion [40–42]. These processes are initiated by cellular protrusions named lamellipodia/filopodia and invadopodia, that have been increasingly recognized as important drivers of local invasion in metastasis [43, 44]. In polarized invading cells, these highly localized events are regulated by specific factors (mRNAs and RNA binding proteins), which often exist at high concentrations at the leading edges of cells [45–48]. Some of these RNA binding proteins have been well characterized as key players in cancer progression and metastatization, such as IGF2BPs [49, 50] and IMPs [51].
Our data demonstrate that FMRP might represent another of these important RNA binding proteins. Indeed, by fluorescent immunocytochemistry, immunogold TEM, and time-lapse live imaging we showed that FMRP localizes, in form of large granules, inside pseudopodia protrusions generating at the leading edge of migrating cells. The FMRP granules were well characterized in neurons and correspond to large ribonucleoprotein (RNP) complexes containing translationally inhibited mRNAs [39], that move along dendrites through the motor proteins kinesin KIF3C [52, 53], dynein [53] and myosin Va [54, 55]. Similar granules, containing FMRP and translationally silent mRNAs, were also observed in pseudopodial protrusions of migrating fibroblasts [56].
The crucial role of some RNA binding proteins (such as IMP proteins) in regulating local protein synthesis in invadopodia has been previously demonstrated [51]. Here we demonstrated for the first time that also FMRP localizes inside invadopodia, both in iCCA and melanoma cells.
In our GDA experiments, the partial correspondence between FMRP staining and F-actin puncta, as well as the partial correspondence between FMRP puncta and gelatin degradation areas, suggests an early and/or late role of FMRP in invadopodia formation, during those preparatory stages, in which local protein synthesis and mRNA metabolism regulation could be of key importance to guarantee the correct assembly and function of these protrusions. This hypothesis was confirmed by the observation that FMRP is able to bind several mRNAs codifying key proteins for invadopodia formation and function, such as Cortactin, Metalloproteinase 1 and 9 and Src, in addition to binding its own mRNA as observed also in neurons [57, 58]. Despite MMP9 and CTTN are known mRNA targets of FMRP in neurons [11, 59–61], the mRNAs identified in our study represent the first FMRP mRNA targets in iCCA cells. Due to the importance of their encoded proteins in orchestrating the molecular events that occurs in invadopodia during their cycle (formation, stabilization, MMP secretion, and dissolution), these mRNAs represent interesting effector molecules through which FMRP may have an impact on invadopodia formation and membrane plasticity at the leading edges of invading iCCA cells (Fig. 8).
FMRP can regulate different aspects of mRNA metabolism of its target mRNAs, such as their transport [52, 62], stability [63–66], editing [67, 68] and translation [10, 69, 70]. Our evidence that FMRP knockdown decreases Cortactin expression but does not affect the expression of the other bound mRNAs, suggests that FMRP could exert its action as translational or stability regulator for Cortactin mRNA, but could regulate aspects of mRNA metabolism that don’t affect protein expression (e.g., editing or transport) for the other targeted mRNAs. In agreement with this idea, we observed a direct correlation between FMRP and Cortactin expression in iCCA tissues, iCCA cell lines and in xenograft tumors from FMR1 silenced HuCCT cells injected in nude mice.
In conclusion, despite further studies are required to demonstrate the role of FMRP as molecular prognostic marker of iCCA, our data shaded light on a possible FMRP-dependent pathogenetic mechanism in iCCA. Specifically, cancer cells could take opportunistic advantage from FMRP overexpression, increasing their migratory and invasive capabilities through the local regulation of key proteins involved in plasma membrane plasticity and invadopodia formation and function at the leading edges.
Materials and methods
Human tissues collection and patient information
iCCA and eCCA samples from patients used in this study were provided by Pathology Department of Campus Bio-Medico University (Rome, Italy). All experiments involving human specimens are conformed to the principles described in the NMA declaration of Helsinki. All human tissues were collected following standardized procedures and informed consent was obtained for all specimens linked with clinical data, according to procedures approved by the Institutional Ethical Board of the Campus Bio-Medico University. The histopathological diagnoses of the tumors were described according to the World Health Organization (WHO) International Classification of Disease for Oncology. Only patients with another neoplasm or with insufficient material for analysis were excluded. The medical records of all patients were examined to obtain clinical and histopathological information.
Immunohistochemical analysis
FMRP IHC was performed using polyclonal antibody ab17722 (Abcam, Cambridge, MA) (1:50 dilution), while Cortactin IHC was performed using monoclonal anti-Cortactin 771716 (R&D System, Minneapolis, MN, USA) (1:200 dilution), according to the protocol reported in Supplementary Information.
Cell cultures
The SV40-transformed (i.e., immortalized) intrahepatic normal human biliary epithelial cell line H69, the human iCCA cell lines HuH28 and HuCCT and the eCCA cell lines KMBC, TFK1, and MzChA1 have been described before [71] and were generously shared by Dr. J Banales (BioDonostia Institute and CIBERehd, San Sebastian, Spain). Cells were cultured in Dulbecco’s modified Eagle’s medium F12 (DMEM-F12, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco, MD, USA) and antibiotics (50 U/ml penicillin, 50 μg/ml streptomycin, Thermo Fisher Scientific, Waltham, MA, USA) at 37 °C in a humidified atmosphere of 5% CO2 (Heraeus, Hanau, Germany). Before use, each cell culture was tested for mycoplasma contamination.
RT-qPCR
Total RNA from cell lines was extracted using the automated Maxwell system from Promega (Madison, WI). Quantitative reverse transcription PCR was performed as reported, and gene expression was normalized relative to that of the housekeeping gene histone H3 as described [72]. Primer sequences for qPCR were: for FMR1 sense 5ʹ-ACAGAGGAAGAGAGGGAGAGC-3ʹ and antisense 5ʹ-CCTTTCATTATTGCAGTCAACTC-3ʹ; for H3: sense 5ʹ-AAAGCCGCTCGCAAGAGTGCG-3ʹ and antisense 5ʹ-CCTTTCATTATTGCAGTCAACTC-3ʹ.
Western blotting
Cellular lysates were prepared as previously reported [16] and western blotting was performed according to the protocol reported in Supplementary Information.
Immuno transmission electron microscopy
Immuno Transmission Electron Microscopy (iTEM) was performed as reported [16] using anti-FMRP (1:5) and anti-Cortactin (1:10) antibodies. The grids were then incubated for 1 h with goat anti-rabbit IgG (1:5) conjugated with 25 nm colloidal-gold particles (British Biocell, Cardiff, United Kingdom) and with anti-mouse IgG (1:5) conjugated with 15 nm colloidal-gold particles (British Biocell, Cardiff, United Kingdom), counterstained in uranyl acetate to underline the cell morphology, and observed with EM 109 electron microscope (Zeiss, Oberkochen, Germany).
Transient silencing of FMRP in HuH28 cells
Small interfering RNA-mediated silencing of FMRP were performed with FMR1-specific siRNAs from Life Technologies (AM 16708, ID #10824, #10919 and #11010). As a nonspecific control, a scramble siRNA was used (#4390843; Life Technologies, Waltham, MA). siRNAs were transfected into HuH28 cells using Lipofectamine RNAiMAX (Life Technologies, Waltham, MA), according to manufacturer’s instructions. Transfections were carried out in six-well plates at 40% confluence with 90 pmol of siRNAs, and HuH28 cells were harvested after 24, 48, or 72 h.
Stable silencing of FMRP in HuCCT cells
Lentiviral vectors (pGFP-shLenti) with FMR1-specific or control CTR-shRNAs (cat. # TL312955) were from OriGene Technologies (Rockville, MD). Lentiviral particles were prepared in 293 T cells using the Lenti-Vpak packaging kit (cat. # TR30037), also from OriGene Technologies, following the manufacturer’s instructions. HuCCT cells were sown in six wells plates (25 × 104 cells/well) and were incubated with FMR1-shRNA, or CTR-shRNAs lentiviral particles for 36 h. Then cells were washed, and 36 h later puromycin (0.25 μg/ml) (Sigma, St. Louis, MO) was added to the medium to start selection.
Tumor xenograft model
The subcutaneous tumor model was established in male athymic nude mice (8 weeks old, n = 6 per group) (Envigo, Valencia, Spain) essentially as described [73]. Briefly, cells (1 × 107) were resuspended in 50 μl phosphate buffer (PBS) plus 50 μl Matrigel (from Corning, Corning, NY) and subcutaneously injected in the right flank of mice. Tumor growth was measured with a Vernier caliper using the formula V = (length x width2)/2. Animal studies were approved by the Animal Care Committee of the University of Navarra (protocol number 159/14). No randomization method was applied, because no different experimental groups with different treatments were processed.
Transient overexpression of FMRP in HuCCT cells
The pRRL-hFMR1-GFP lentiviral vector expressing the Iso7 isoform of human FMRP fused to eGFP was a generous gift by Prof. Suzanne Zukin (Albert Einstein College of Medicine, NY, USA) to CB. The pRRL-hFMR1-GFP or the empty eGFP vector as control were transiently transfected into HuCCT cells using Lipofectamine 3000 (Life Technologies), according to manufacturer’s instructions. Transfections were carried out in six-well plates at 70% confluence with 3 μg of pRRL-hFMR1-GFP vector (or eGFP vector) and HuCCT cells were harvested after 24, 48, or 72 h.
Time-lapse live imaging
HuCCT cells overexpressing FMRP-GFP or eGFP were sown in fibronectin-coated chambers and placed in epifluorescence microscope incubator for a time-lapse live imaging experiment as described in Supplementary Information.
Scratch assay
Scratch assay was performed as previously described [16] and detailed in Supplementary Information.
Trans-well migration and invasion assays
Trans-well migration and invasion assays were performed as described [16] and detailed in Supplementary Information.
Immunofluorescence (IF)
Immunofluorescence experiments were performed as reported in Supplementary Information.
GDA
Eight well chamber slides were coated with 0.2% Cy3-gelatin (ECM671, Merck KGaA, Darmstadt, Germany) according to the datasheet. 40% confluent HuH28 cells were detached, plated in completed media (4000 cells for well) and left to degrade the Cy3-gelatin for 19 or 24 h, as described [74]. For GDA experiments with HuCCT, before seeding, 40% confluent cells were starved for 24 h in 2% FBS D-MEM medium. Then the cells were detached and sown on Cy3-gelatin coated chamber slides (4000 cells for chamber) in completed media containing 25 μM MMP inhibitor (GM6001, Merck KGaA, Darmstadt, Germany) to block GD. After 16 h, MMP inhibitor was removed and the cells were left to degrade Cy3-gelatin for 2 or 4 h in completed media. Then IF experiments were performed in the above described conditions. Images were captured with a NIKON TiA1 confocal as a z-stack series using the NIS element software and processed with Fiji software (US National Institutes of Health).
Immunoprecipitation
HuH28 Cells were lysed as reported [13] and IP was performed using Dynabeads Protein G immunoprecipitation kit (Life Technologies, Waltham, MA) according to manufacturer’s protocol. RNA was Trizol (Life technologies, Waltham, MA) extracted, isopropanol precipitated and quantified by BioSpectrometer® (Eppendorf).
NanoString nCounter® analysis
One hundred ng of total RNAs from co-IP RNAs or inputs (HuH28 cytoplasmic extracts) were subjected to NanoString nCounter® analysis, using a custom gene set containing 14 selected target genes ACTR3B, CTTN, FMR1, LRP4, MMP1, MMP10, MT1-MMP, MMP2, MMP9, MUSK, SH3PXD2A, SRC, TIMP-2, N-WASP, and three housekeeping genes, GAPDH, HPRT1, and TUBB. NanoString nCounter® analysis was performed following the manufacturer’s protocol (www.nanostring.com). Raw counts for each mRNA were normalised and analysed using nSolver Analysis Software (nSAS) to obtained differential expression analysis of 17 mRNAs in FMRP co-IP RNA samples versus IgG co-IP RNA samples.
Statistical analysis
Results are presented as mean ± SE or mean ± SD or as boxplots showing the individual data points, the median values and the variability beyond the upper and lower quartiles, with experiment numbers indicated in the figure legends. Statistical significance was assessed using the Mann–Witney test or the Student’s t test, according to non-normal or normal distribution respectively. P < 0.05 was accepted as statistically significant. The investigators were blinded to the group allocation during the experiments and/or when assessing the outcome.
Supplementary information
Acknowledgements
This research was supported by FIRB 2010 funds (RBAP10447J_005) to RAR, by Pathology Dept. and Predictive Molecular Diagnostic Division funds to GP, by private funds to SM and by Hepacare Project from Fundación La Caixa, AECC Grant for Rare and Childhood cancers 2017 call, grant FIS PI16/01126 from Instituto de Salud Carlos III, grant 58/17 from Gobierno de Navarra Salud, grant PID2019-104878RB-100/AEI/10.13039/501100011033 from FEDER/Ministerio de Ciencia, Innovación y Universidades-Agencia Estatal de Investigación, and Fundación Eugenio Rodriguez Pascual to MAA and MGF-B. MGF-B is a Ramón y Cajal Fellow (RYC2018-00244475-1) and LC is a predoctoral fellow of the Gobierno de Navarra. GP was supported by the Italian Fragile X Association and PRIN2017 89LFKB and Etat de Vaud to CB. We thank Franca Abbruzzese for technical help with time lapse confocal acquisitions and Prof. R. Suzanne Zukin for the plasmid expressing human FMRP.
Compliance with ethical standards
Conflict of interest
The authors declare no competing interests.
Footnotes
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
These authors contributed equally: Simone Carotti, Maria Zingariello.
Contributor Information
Sergio Morini, Email: s.morini@unicampus.it.
Francesca Zalfa, Email: f.zalfa@unicampus.it.
Supplementary information
The online version contains supplementary material available at 10.1038/s41388-021-01824-3.
References
- 1.Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD, Khan SA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Hepatol. 2020;72:95–103. doi: 10.1016/j.jhep.2019.09.007. [DOI] [PubMed] [Google Scholar]
- 2.Sirica AE, Gores GJ, Groopman JD, Selaru FM, Strazzabosco M, Wei Wang X, et al. Intrahepatic cholangiocarcinoma: continuing challenges and translational advances. Hepatology. 2019;69:1803–15. doi: 10.1002/hep.30289. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Rizvi S, Kan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma—evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15:95–111. doi: 10.1038/nrclinonc.2017.157. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Bagni C, Tassone F, Neri G, Hagerman R. Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics. J Clin Invest. 2012;122:4314–22. doi: 10.1172/JCI63141. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Bagni C, Zukin RS. A synaptic perspective of fragile X syndrome and autism spectrum disorders. Neuron. 2019;101:1070–88. doi: 10.1016/j.neuron.2019.02.041. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Bagni C, Oostra BA. Fragile X syndrome: from protein function to therapy. Am J Med Genet A. 2013;161A:2809–21. doi: 10.1002/ajmg.a.36241. [DOI] [PubMed] [Google Scholar]
- 7.Bhakar AL, Dolen G, Bear MF. The pathophysiology of fragile X (and what it teaches us about synapses) Annu Rev Neurosci. 2012;35:417–43. doi: 10.1146/annurev-neuro-060909-153138. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Gross C, Barry-Kravis EM, Bassell GJ. Therapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond. Neuropsychoparmacology. 2012;37:178–95. doi: 10.1038/npp.2011.137. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Miyashiro KY, Beckel-Mitchener A, Purk TP, Becker KG, Barret T, Liu L, et al. RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice. Neuron. 2003;37:417–31. doi: 10.1016/s0896-6273(03)00034-5. [DOI] [PubMed] [Google Scholar]
- 10.Darnell JC, Van Driesche SJ, Zhang C, Hung KY, Mele A, Fraser CE, et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell. 2011;146:247–61. doi: 10.1016/j.cell.2011.06.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Ascano M, Jr, Mukherjee N, Bandaru P, Miller JB, Nusbaum JD, Corcoran DL, et al. FMRP targets distinct mRNA sequence elements to regulate protein expression. Nature. 2012;492:382–6. doi: 10.1038/nature11737. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Maurin T, Lebrigand K, Castagnola S, Paquet A, Jarjat M, Popa A, et al. HITS-CLIP in various brain areas reveals new targets and new modalities of RNA binding by fragile X mental retardation protein. Nucleic Acids Res. 2018;46:6344–55. doi: 10.1093/nar/gky267. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Lucà R, Averna M, Zalfa F, Vecchi M, Bianchi F, La Fata G, et al. The fragile X protein binds mRNAs involved in cancer progression and modulates metastasis formation. EMBO Mol Med. 2013;5:1523–36. doi: 10.1002/emmm.201302847. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Xing Z, Zeng M, Hu H, Zhang H, Hao Z, Long Y, et al. Fragile X mental retardation protein promotes astrocytoma proliferation via the MEK/ERK signaling pathway. Oncotarget. 2016;7:75394–406. doi: 10.18632/oncotarget.12215. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Srivastava A. A novel link between FMR gene and the JNK pathway provides clues to possible role in malignant pleural mesothelioma. FEBS Open Bio. 2015;5:705–11. doi: 10.1016/j.fob.2015.07.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Zalfa F, Panasiti V, Carotti S, Zingariello M, Perrone G, Sancillo L, et al. The fragile X mental retardation protein regulates tumor invasiveness-related pathways in melanoma cells. Cell Death Dis. 2017;8:e3169. doi: 10.1038/cddis.2017.521. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Di Grazia A, Marafini I, Pedini G, Di Fusco D, Laudisi F, Dinallo V, et al. The fragile X mental retardation protein regulates RIP1K and colorectal cancer resistance to necroptosis. Cell Mol Gastroenterol Hepatol. 2020;20:30172–7. doi: 10.1016/j.jcmgh.2020.10.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Schultz-Pedersen S, Hasle H, Olsen JH, Friedrich U. Evidence of decreased risk of cancer in individuals with fragile X. Am J Med Genet. 2001;103:226–30. [PubMed] [Google Scholar]
- 19.Kalkunte R, Macarthur D, Morton R. Glioblastoma in a boy with fragile X: an unusual case of neuroprotection. Arch Dis Child. 2007;92:795–6. doi: 10.1136/adc.2006.103382. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Kurokawa Y, Matoba R, Takemasa I, Nakamori S, Tsujie M, Nagano H, et al. Molecular features of non-B, non-C hepatocellular carcinoma: a PCR-array gene expression profiling study. J Hepatol. 2003;39:1004–12. doi: 10.1016/s0168-8278(03)00473-2. [DOI] [PubMed] [Google Scholar]
- 21.Liu Y, Zhu X, Zhu J, Liao S, Tang Q, Liu K, et al. Identification of differential expression of genes in hepatocellular carcinoma by suppression subtractive hybridization combined cDNA microarray. Oncol Rep. 2007;18:943–51. [PubMed] [Google Scholar]
- 22.Li Y, Tang Y, Ye L, Liu B, Liu K, Chen J, et al. Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastasis-related genes through cDNA microarray. J Cancer Res Clin Oncol. 2003;129:43–51. doi: 10.1007/s00432-002-0396-4. [DOI] [PubMed] [Google Scholar]
- 23.Li L, Zeng Q, Bhutkar A, Galván JA, Karamitopoulou E, Noordermeer D, et al. GKAP acts as a genetic modulator of NMDAR signaling to govern invasive tumor growth. Cancer Cell. 2018;33:736–51. doi: 10.1016/j.ccell.2018.02.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Dianat N, Dubois-Pot-Schneider H, Steichen C, Desterke C, Leclerc P, Raveux A, et al. Generation of functional cholangiocyte-like cells from human pluripotent stem cells and HepaRG cells. Hepathology. 2014;60:700–14. doi: 10.1002/hep.27165. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Kusaka Y, Tokiwa T, Sato J. Establishment and characterization of a cell line from a human cholangiocellular carcinoma. Res Exp Med. 1988;188:367–75. doi: 10.1007/BF01851205. [DOI] [PubMed] [Google Scholar]
- 26.Weed SA, Parsons JT. Cortactin: coupling membrane dynamics to cortical actin assembly. Oncogene. 2001;20:6418–34. doi: 10.1038/sj.onc.1204783. [DOI] [PubMed] [Google Scholar]
- 27.Arjonen A, Kaukonen R, Ivaska J. Filopodia and adhesion in cancer cell motility. Cell Adhes Migr. 2011;5:421–30. doi: 10.4161/cam.5.5.17723. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Macgrath SM, Koleske AJ. Cortactin in cell migration and cancer at a glance. J Cell Sci. 2012;125:1621–6. doi: 10.1242/jcs.093781. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Chen WT, Wang JY. Specialized surface protrusions of invasive cells, invadopodia and lamellipodia, have differential MT1-MMP, MMP-2, and TIMP-2 localization. Ann N. Y Acad Sci. 1999;30:361–71. doi: 10.1111/j.1749-6632.1999.tb07695.x. [DOI] [PubMed] [Google Scholar]
- 30.Murphy DA, Courtneidge SA. The ‘ins’ and ‘outs’ of podosomes and invadopodia: characteristics, formation and function. Nat Rev Mol Cell Biol. 2011;12:413–26. doi: 10.1038/nrm3141. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Beaty BT, Condeelis J. Digging a little deeper: the stages of invadopodium formation and maturation. Eur J Cell Biol. 2014;93:438–44. doi: 10.1016/j.ejcb.2014.07.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Wang Y, Li J, Xia Y, Gong R, Wang K, Yan Z, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 2013;31:1188–95. doi: 10.1200/JCO.2012.41.5984. [DOI] [PubMed] [Google Scholar]
- 33.Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg. 2014;149:565–74. doi: 10.1001/jamasurg.2013.5137. [DOI] [PubMed] [Google Scholar]
- 34.Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, et al. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) Nat Rev Gastroenterol Hepatol. 2016;13:261–80. doi: 10.1038/nrgastro.2016.51. [DOI] [PubMed] [Google Scholar]
- 35.Rizvi S, Gores GJ. Emerging molecular therapeutic targets for cholangiocarcinoma. J Hepatol. 2017;67:632–44. doi: 10.1016/j.jhep.2017.03.026. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. doi: 10.1016/j.cell.2011.02.013. [DOI] [PubMed] [Google Scholar]
- 37.Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009;28:15–33. doi: 10.1007/s10555-008-9169-0. [DOI] [PubMed] [Google Scholar]
- 38.Christofori G. New signals from the invasive front. Nature. 2006;441:444–50. doi: 10.1038/nature04872. [DOI] [PubMed] [Google Scholar]
- 39.Ferrari F, Mercaldo V, Piccoli G, Sala C, Cannata S, Achsel T, et al. The fragile X mental retardation protein-RNP granules show an mGluR-dependent localization in the post-synaptic spines. Mol Cell Neurosci. 2007;34:343–54. doi: 10.1016/j.mcn.2006.11.015. [DOI] [PubMed] [Google Scholar]
- 40.Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature. 2012;485:55–61. doi: 10.1038/nature10912. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Silvera D, Formenti SC, Schneider RJ. Translational control in cancer. Nat Rev Cancer. 2010;10:254–66. doi: 10.1038/nrc2824. [DOI] [PubMed] [Google Scholar]
- 42.Stumpf CR, Ruggero D. The cancerous translation apparatus. Curr Opin Genet Dev. 2011;21:474–83. doi: 10.1016/j.gde.2011.03.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Bravo-Cordero JJ, Hodgson L, Condeelis J. Directed cell invasion and migration during metastasis. Curr Opin Cell Biol. 2012;24:277–83. doi: 10.1016/j.ceb.2011.12.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Eddy RJ, Weidmann MD, Sharma VP, Condeelis JS. Tumor cell invadopodia: invasive protrusions that orchestrate metastasis. Trends cell Biol. 2017;27:595–607. doi: 10.1016/j.tcb.2017.03.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Insall RH, Machesky LM. Actin dynamics at the leading edge: from simple machinery to complex networks. Dev Cell. 2009;17:310–22. doi: 10.1016/j.devcel.2009.08.012. [DOI] [PubMed] [Google Scholar]
- 46.Ridley AJ. Life at the leading edge. Cell. 2011;145:1012–22. doi: 10.1016/j.cell.2011.06.010. [DOI] [PubMed] [Google Scholar]
- 47.Pollard TD, Cooper JA. Actin a central player in cell shape and movement. Science. 2009;326:1208–12. doi: 10.1126/science.1175862. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Liao G, Mingle L, Van De Water L, Liu G. Control of cell migration through mRNA localization and local translation. Wiley Interdiscip Rev RNA. 2015;6:1–15. doi: 10.1002/wrna.1265. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Taniuchi K, Furihata M, Hanazaki K, Saito M, Saibara T. IGF2BP3-mediated translation in cell protrusions promotes cell invasiveness and metastasis of pancreatic cancer. Oncotarget. 2014;5:6832–45. doi: 10.18632/oncotarget.2257. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Bell JL, Wachter K, Mühleck B, Pazaitis N, Köhn M, Lederer M, et al. Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression? Cell Mol Life Sci. 2013;70:2657–75. doi: 10.1007/s00018-012-1186-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Vikesaa J, Hansen TV, Jønson L, Borup R, Wewer UM, Christiansen J, et al. RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J. 2006;25:1456–68. doi: 10.1038/sj.emboj.7601039. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Davidovic L, Jaglin XH, Lepagnol-Bestel AM, Tremblay S, Simonneau M, Bardoni B, et al. The fragile X mental retardation protein is a molecular adaptor between the neurospecific KIF3C kinesin and dendritic RNA granules. Hum Mol Genet. 2007;16:3047–58. doi: 10.1093/hmg/ddm263. [DOI] [PubMed] [Google Scholar]
- 53.Dictenberg JB, Swanger SA, Antar LN, Singer RH, Bassell GJ. A direct role for FMRP in activity-dependent dendritic mRNA transport links filopodial-spine morphogenesis to fragile X syndrome. Dev Cell. 2008;14:926–39. doi: 10.1016/j.devcel.2008.04.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Lindsay AJ, McCaffrey MW. Myosin Va is required for the transport of fragile X mental retardation protein (FMRP) granules. Biol Cell. 2014;106:57–71. doi: 10.1111/boc.201200076. [DOI] [PubMed] [Google Scholar]
- 55.Ohashi S, Koike K, Omori A, Ichinose S, Ohara S, Kobayashi S, et al. Identification of mRNA/protein (mRNP) complexes containing Puralpha, mStaufen, fragile X protein, and myosin Va and their association with rough endoplasmic reticulum equipped with a kinesin motor. J Biol Chem. 2002;277:37804–10. doi: 10.1074/jbc.M203608200. [DOI] [PubMed] [Google Scholar]
- 56.Mili S, Moissoglu K, Macara IG. Genome-wide screen reveals APC-associated RNAs enriched in cell protrusions. Nature. 2008;453:115–9. doi: 10.1038/nature06888. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Schaeffer C, Bardoni B, Mandel JL, Ehresmann B, Ehresmann C, Moine H. The fragile X mental retardation protein binds specifically to its mRNA via a purine quartet motif. EMBO J. 2001;20:4803–13. doi: 10.1093/emboj/20.17.4803. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Didiot MC, Tian Z, Schaeffer C, Subramanian M, Mandel JL, Moine H. The G-quartet containing FMRP binding site in FMR1 mRNA is a potent exonic splicing enhancer. Nucleic Acids Res. 2008;36:4902–12. doi: 10.1093/nar/gkn472. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Janusz A, Milek J, Perycz M, Pacini L, Bagni C, Kaczmarek L, et al. The Fragile X mental retardation protein regulates matrix metalloproteinase 9 mRNA at synapses. J Neurosci. 2013;33:18234–41. doi: 10.1523/JNEUROSCI.2207-13.2013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Sidhu H, Dansie LE, Hickmott PW, Ethell DW, Ethell IM. Genetic removal of matrix metalloproteinase 9 rescues the symptoms of fragile X syndrome in a mouse model. J Neurosci. 2014;34:9867–79. doi: 10.1523/JNEUROSCI.1162-14.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Gkogkas CG, Khoutorsky A, Cao R, Jafarnejad SM, Prager-Khoutorsky M, Giannakas N, et al. Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes. Cell Rep. 2014;9:1742–55. doi: 10.1016/j.celrep.2014.10.064. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Kao DI, Aldridge GM, Weiler IJ, Greenough WT. Altered mRNA transport, docking, and protein translation in neurons lacking fragile X mental retardation protein. Proc Natl Acad Sci U.S.A. 2010;107:15601–6. doi: 10.1073/pnas.1010564107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.D’Hulst C, De Geest N, Reeve SP, Van Dam D, De Deyn PP, Hassan BA, et al. Decreased expression of the GABAA receptor in fragile X syndrome. Brain Res. 2006;1121:238–45. doi: 10.1016/j.brainres.2006.08.115. [DOI] [PubMed] [Google Scholar]
- 64.Zalfa F, Eleuteri B, Dickson KS, Mercaldo V, De Rubeis S, Di, et al. A new function for the fragile X mental retardation protein in regulation of PSD-95 mRNA stability. Nat Neurosci. 2007;10:578–87. doi: 10.1038/nn1893. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Zhang M, Wang Q, Huang Y. Fragile X mental retardation protein FMRP and the RNA export factor NXF2 associate with and destabilize Nxf1 mRNA in neuronal cells. Proc Natl Acad Sci U.S.A. 2007;104:10057–62. doi: 10.1073/pnas.0700169104. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.De Rubeis S, Bagni C. Fragile X mental retardation protein control of neuronal mRNA metabolism: insights into mRNA stability. Mol Cell Neurosci. 2010;43:43–50. doi: 10.1016/j.mcn.2009.09.013. [DOI] [PubMed] [Google Scholar]
- 67.Bhogal B, Jepson JE, Savva YA, Pepper AS, Reenan RA, Jongens TA. Modulation of dADAR-dependent RNA editing by the Drosophila fragile X mental retardation protein. Nat Neurosci. 2011;14:1517–24. doi: 10.1038/nn.2950. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Filippini A, Bonini D, Lacoux C, Pacini L, Zingariello M, Sancillo L, et al. Absence of the fragile X mental retardation protein results in defects of RNA editing of neuronal mRNAs in mouse. RNA Biol. 2017;14:1580–91. doi: 10.1080/15476286.2017.1338232. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Zalfa F, Giorgi M, Primerano B, Moro A, Di Penta A, Reis S, et al. The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses. Cell. 2003;112:317–27. doi: 10.1016/s0092-8674(03)00079-5. [DOI] [PubMed] [Google Scholar]
- 70.Napoli I, Mercaldo V, Boyl PP, Eleuteri B, Zalfa F, De Rubeis S, et al. The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP. Cell. 2008;134:1042–54. doi: 10.1016/j.cell.2008.07.031. [DOI] [PubMed] [Google Scholar]
- 71.Zach S, Birgin E, Ruckert F. Primary cholangiocellular carcinoma cell lines. J Stem Cell Res Transpl. 2015;2:1013. [Google Scholar]
- 72.Elizalde M, Urtasun R, Azkona M, Latasa MU, Goñi S, García-Irigoyen O, et al. Splicing regulator SLU7 is essential for maintaining liver homeostasis. J Clin Invest. 2014;124:2909–20. doi: 10.1172/JCI74382. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Bárcena-Varela M, Caruso S, Llerena S, Álvarez-Sola G, Uriarte I, Latasa MU, et al. Dual targeting of histone methyltransferase G9a and DNA-methyltransferase 1 for the treatment of experimental hepatocellular carcinoma. Hepatology. 2019;69:587–603. doi: 10.1002/hep.30168. [DOI] [PubMed] [Google Scholar]
- 74.Vira VA, Kenneth MY, Susette C, Mueller ECM. Degradation assays for analyzing local cell invasion. Methods in molecular biology. Extracell Matrix Protoc. 2009;522:211–9. doi: 10.1007/978-1-59745-413-1_15. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.